Please find on the next pages the holding of the Novo Nordisk shares and Novo Nordisk share options as of the closure of the trading window as reported to Novo Nordisk.
The share portfolio
|
|
Holding of shares
14 May 2004 |
Movements
since 14 May 2004 |
Portfolio as per
26 August 2004 | ||
|
|
|
Bought |
Sold |
Total shareholding
Number of shares |
Market value of total shareholding in DKK |
|
Board of Directors: |
|
|
|
|
|
|
Mads Øvlisen |
17,330 |
0 |
0 |
17,330 |
5,580,260 |
|
Sten Scheibye |
400 |
0 |
0 |
400 |
128,800 |
|
Kurt Briner |
2,400 |
0 |
0 |
2,400 |
772,800 |
|
Johnny Henriksen |
300 |
0 |
0 |
300 |
96,600 |
|
Niels Jacobsen |
11,000 |
0 |
0 |
11,000 |
3,542,000 |
|
Ulf J. Johansson |
0 |
0 |
0 |
0 |
0 |
|
Anne Marie Kverneland |
1,600 |
0 |
0 |
1,600 |
515,200 |
|
Kurt Anker Nielsen |
27,440 |
0 |
3,000 |
24,440 |
7,869,680 |
|
Stig Strøbæk |
400 |
0 |
0 |
400 |
128,800 |
|
Jørgen Wedel |
5,555 |
0 |
0 |
5,555 |
1,788,710 |
|
Board of Directors in total: |
66,425 |
0 |
3,000 |
63,425 |
20,422,850 |
|
|
|
|
|
|
|
|
Executive Management: |
|
|
|
|
|
|
Lars Rebien Sørensen |
3,800 |
0 |
0 |
3,800 |
1,223,600 |
|
Jesper Brandgaard |
5,545 |
0 |
0 |
5,545 |
1,785,490 |
|
Lars Almblom Jørgensen |
8,690 |
0 |
0 |
8,775 |
2,798,180 |
|
Lise Kingo |
1,555 |
0 |
0 |
1,555 |
500,710 |
|
Kåre Schultz |
5,000 |
0 |
0 |
5,000 |
1,610,000 |
|
Mads Krogsgaard Thomsen |
8,835 |
0 |
8,735 |
100 |
32,200 |
|
Executive Management in total: |
33,425 |
0 |
8,735 |
24,690 |
7,950,180 |
|
|
|
|
|
|
|
|
All insiders and connected persons in total: |
|
|
|
647,135 |
208,377,470 |
For background information and definitions, please see below.
The share option portfolio - Board of Directors
|
Granted |
Exercise
period |
Options
outstanding 14 May 2004 |
Exercised since
14 May 2004 |
Outstanding
26 August 2004 |
Exercise
price |
Market
value of
options (DKK million) |
|
|
|
|
|
|
|
|
|
1999 |
2003-08 |
19,500 |
0 |
19,500 |
198 |
3 |
|
|
|
|
|
|
|
|
|
2000 |
2004-07 |
95,920 |
0 |
95,920 |
198 |
13 |
|
|
|
|
|
|
|
|
|
2000 |
2004-09 |
21,000 |
0 |
21,000 |
198 |
3 |
|
|
|
|
|
|
|
|
|
Total |
|
136,420 |
0 |
136,420 |
|
19 |
|
|
|
|
|
|
|
|
The share option portfolio - Executive Management
|
Granted |
Exercise
period |
Options
outstanding 14 May 2004 |
Exercised
since
14 May 2004 |
Outstanding
26 August 2004 |
Exercise
price |
Market
value of
options (DKK million) |
|
|
|
|
|
|
|
|
|
1998 |
2001-06 |
10,500 |
0 |
10,500 |
190 |
1 |
|
|
|
|
|
|
|
|
|
1998 |
2002-07 |
17,000 |
0 |
17,000 |
125 |
3 |
|
|
|
|
|
|
|
|
|
1999 |
2003-08 |
37,500 |
0 |
37,500 |
198 |
5 |
|
|
|
|
|
|
|
|
|
2000 |
2004-07 |
200,140 |
0 |
200,140 |
198 |
28 |
|
|
|
|
|
|
|
|
|
2000 |
2004-09 |
35,000 |
0 |
35,000 |
198 |
5 |
|
2001 |
2005-10 |
47,500 |
0 |
47,500 |
332 |
4 |
|
2003 |
2007-12 |
70,000 |
0 |
70,000 |
195 |
11 |
|
|
|
|
|
|
|
|
|
Total |
|
417,640 |
0 |
417,640 |
|
57 |
|
|
|
|
|
|
|
|
Background information and definitions re holding of shares:
What is the trading window?
Novo Nordisk's internal rules on trading in Novo Nordisk securities permit trading in such securities by insiders and connected persons in the 15-calendar-day period following each quarterly announcement.
Who are all insiders and connected persons?
Insiders at Novo Nordisk are defined as members of the Board of Directors, members of Executive Management, senior vice presidents and all employees reporting directly to them, all employees in Corporate Legal, Corporate Finance, Investor Relations and Corporate Communications, elected auditors and their deputies as well as certain other employees who by the general counsel have been categorised as insiders. Further, insiders include the following from Novo Nordisk's parent organisation, Novo A/S, and the Novo Nordisk Foundation: members of the Board of Directors, members of Management and other employees who have access to inside information re Novo Nordisk, as well as elected auditors. The insider register at Novo Nordisk comprises a total of approximately 500 people including directors, executives and employees.
This group's reported trading in the Novo Nordisk share also includes trading undertaken by insiders' spouses/cohabitants or children under the age of 18 as well as any company, foundation and/or other businesses controlled by the insider, his/her spouse/cohabitant and/or children under the age of 18 (connected persons). This brings the group to a total of approximately 1,500-2,000 members.
What are ID code and shares?
The ID code DK001028081 is the code (ISIN) of the Novo Nordisk share on the Copenhagen Stock Exchange. Shares include shares listed on the Copenhagen Stock Exchange and London Stock Exchange as well as ADRs listed on New York Stock Exchange, except for ADRs held in 401(k) retirement plan by US-based employees.
What are movements?
Movements comprise shares purchased or otherwise acquired and shares sold or otherwise disposed of. Movements further comprise shareholdings of members of the Board of Directors and/or members of Executive Management taking office during the period under review.
What is market value of the total shareholding?
The market value is the total shareholding of the members of the Board of Directors, of the members of Executive Management and of the insiders and connected persons as a group, respectively, multiplied by the closing share price on the Copenhagen Stock Exchange on 25 August 2004 of DKK 322.
Background information and definitions re holding of options:
As far as options granted in 2000 are concerned, please note that the options granted with an exercise period of 2004-07 relates to the combined 'share investment scheme' and 'option grant scheme' launched in connection with the demerger of Novozymes.
What is market value of options?
The calculation of market values of the options is based on the Black-Scholes option-pricing model. The closing price on the Copenhagen Stock Exchange on 25 August 2004 of DKK 322 is used.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 18,800 full-time employees in 69 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
For further information please contact:
|
Media: |
Investors: |
|
Mike Rulis |
Outside North America: |
|
Tel (direct):
(+45) 4442 3573 |
Peter Haahr |
|
|
Tel (direct):
(+45) 4442 1207 |
|
|
|
|
|
Palle Holm Olesen |
|
|
Tel (direct):
(+45) 4442 6175 |
|
|
|
|
|
In North America: |
|
|
Christian Kanstrup |
|
|
Tel (direct):
(+1) 609 919 7937
|
Stock Exchange Announcement No 54 / 2004